About: ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides Nebula focuses on genomics testing technologies a comprehensive method for analyzing entire genomes, including the genes and chromosomes in deoxyribonucleic acid (DNA). It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Uniondale, New York.
Sector: Healthcare
Industry: Diagnostics & Research
Latest price: $0.02 (-1.14%)
PRPHNASDAQProPhase Labs Inc
ProPhase Labs Inc share price
PRPH price activity
Último preço
$ 0,020
Variação (24h)
-0,00 USD (-1,14%)
Volume
46
Volume (média 4 sem.)
-
Abertura
$ 0,02
Variação do dia
$ 0,02 - $ 0,02
Fechamento anterior
$ 0,02
Último negócio
09 Sep, 5:47 pm GMT+0
Atrasado
09 Sep, 5:47 pm GMT+0
PRPH price performance
Atrasado
09 Sep, 5:47 pm GMT+0
quote.marketSignals